Lys553
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys553  -  GARS (human)

Site Information
GktFQLtkDMINVkR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 10839688

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:
multiple myeloma ( 4 )
Relevant cell line - cell type - tissue:
HEp-2 (squamous) ( 1 ) , HUVEC (endothelial) ( 2 ) , Jurkat (T lymphocyte) ( 1 ) , U266 (plasma cell) ( 4 ) , U2OS (bone cell) ( 3 )

Upstream Regulation
Treatments:
bortezomib ( 2 )

Downstream Regulation
Effects of modification on GARS:
protein degradation ( 2 )

References 

1

Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640
29967540   Curated Info

2

Dieudé M, et al. (2015) The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med 7, 318ra200
26676607   Curated Info

3

Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98
23000965   Curated Info

4

Possemato A (2009) CST Curation Set: 6588; Year: 2009; Biosample/Treatment: cell line, U266/MG132; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.